Listed

Grace Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 10:56 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-04-01 to 2021-06-30$469.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-04-01 to 2021-06-30−$3.1mus-gaap:OperatingIncomeLoss
Net income3 months2021-04-01 to 2021-06-30−$3.1mus-gaap:NetIncomeLoss
Operating cash flow3 months2021-04-01 to 2021-06-30−$3.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-06-30$41.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$60.4mus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$60.5mus-gaap:Assets
Current liabilitiesAt period end2021-06-30$2.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$7.0mus-gaap:Liabilities
Shareholders' equityAt period end2021-06-30$53.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-21-005871. Last ingested by Listed: Nov 14, 2026, 23:10 ET. Listed shows no prices and gives no investment advice.